汇宇制药拟出资1.5亿元参与设立私募基金

Core Viewpoint - The company, Huili Pharmaceutical, announced plans to jointly invest in a new private equity fund focused on the biomedical sector, particularly targeting late-stage clinical projects with clear commercial potential [1] Group 1: Investment Details - Huili Pharmaceutical will collaborate with Hangzhou Xiaochi Private Equity Fund Management Co., Ltd. to establish Chengdu Huili Xiaochi Biomedical Venture Capital Partnership (Limited Partnership) [1] - The initial subscription scale of the private equity fund is set at 400 million yuan, with Huili Pharmaceutical committing 150 million yuan, representing 37.5% of the total initial subscription amount [1]